https://orcid.org/0000-0002-8979-557X
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Purpose
To study the consistency in outcomes of standalone canaloplasty performed via an ab-interno surgical technique in reducing intraocular pressure (IOP) and number of medications in uncontrolled open-angle glaucoma (OAG) eyes over a 12-month period.
Methods
This retrospective multicenter case series included patients who underwent standalone canaloplasty via an ab-interno surgical technique using the iTrack microcatheter (Nova Eye, Inc., Fremont, USA) and had preoperative uncontrolled OAG (IOP≥18mmHg) along with no previous glaucoma surgery. The iTrack microcatheter is used to circumnavigate 360° and viscodilate Schlemm’s canal. Consistency of IOP and medications reduction on an eye-by-eye basis were evaluated to understand the outcomes in each single eye.
Results
Sixty-four eyes of 60 patients (age 71.5±13.4 years) were included. Six eyes (9%) that underwent additional glaucoma surgery were considered a failure and were subsequently excluded from analysis. At 12 months, IOP was reduced in 57 of the 58 (89%) remaining eyes; one eye had the same IOP with a reduced number of medications. Of the 57/58 eyes with a reduced IOP: 44 eyes (69%) required fewer medications; 12 eyes (19%) required the same number of medications. Of these 58 eyes, 78% of eyes had a ≥20% reduction in IOP compared to baseline; 69% eyes had a postoperative IOP ≤15 mmHg, and 86% eyes ≤18 mmHg at 12 months. Forty percent of the eyes were medication-free at 12 months compared to none at baseline.
Conclusion
Canaloplasty performed via an ab-interno surgical technique as a standalone procedure consistently reduced IOP and glaucoma medications in almost all eyes.
Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use:
Data Sharing Statement
All data generated or analysed for this study are included in the article. Further enquiries can be directed to the corresponding author.
Acknowledgments
Assistance in medical writing was provided by GP Communications, funded by Nova Eye Medical.
Disclosure
The authors have no financial or proprietary interest in any material or method mentioned. Dr Khaimi is Nova Eye Medical Chief Medical Consultant for the iTrack. Prof. Koerber is the Principal Investigator for the CATALYST clinical study which uses the product mentioned in this article (iTrack, Nova Eye Medical). Dr Ondrejka is an investigator for the CATALYST study. Dr Gallardo is a consultant of Nova Eye Medical and Sight Science.